Hereditary Transthyretin Amyloidosis (hATTR) Market
Transthyretin Amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body’s organs and tissues.
hATTR is a systemic autosomal dominant disorder characterized by the extracellular deposition of misfolded TTR protein. hATTR cases are divided into two segments which include Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases.
Hereditary Transthyretin Amyloidosis (hATTR) Market Key Facts
In 2017, the total diagnosed prevalent population of hATTR in the 7MM was 11,330.
hATTR is segmented into two groups, i.e., Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2017, there were 5,241, and 6,089 diagnosed prevalent cases of FAP and FAC, respectively, in the 7MM.
Hereditary Transthyretin Amyloidosis (hATTR) Market
The market size of Hereditary Transthyretin Amyloidosis (hATTR) shall increase during the forecast period (2020–2030), owing to the launch of upcoming therapies.
The Hereditary Transthyretin Amyloidosis (hATTR) market analysis report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Transthyretin Amyloidosis (hATTR) market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
For more details, visit:
https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market
High-grade Glioma Market
Highly Malignant or High-Grade Gliomas (HGG) are tumours of the central nervous system (CNS). They are solid tumours arising from transformed cells called astrocytes of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumours, thereby differentiating them from malignant tumours of other organs that have spread (metastasised) to the CNS.
High-grade Glioma Market Key Facts
According to The Royal Marsden, NHS Foundation Trust, HGG are the most common type of adult brain tumour and although they look the same under the microscope, they may be different biologically. Less than 30 children a year develop high grade glioma in the UK. This is about 8% of all childhood brain and spinal cord tumours.
As per a study conducted by Yiallouros et al. titled “High-Grade Gliomas (HGG) - Brief Information”, HGGs account for approximately 15-20 % of CNS tumours in children and adolescents. Each year, about 60-80 children and adolescents younger than 15 years of age are newly diagnosed with a HGG. This corresponds to an incidence rate of 5-10 new diagnoses per 1.000.000 children per year.
High-grade Glioma Market
The High-grade Glioma market analysis report helps to build the detailed comprehension of the historic, current and forecasted High-grade Glioma market trends by evaluating the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of High-grade Glioma market Size and Share analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
For more information on High-grade Glioma Market, visit:
https://www.delveinsight.com/report-store/high-grade-glioma-market
Hemophagocytic Lymphohistiocytosis Market
Hemophagocytic lymphohistiocytosis is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems.
Hemophagocytic Lymphohistiocytosis Market Key Facts
As per the John Hopkins Medicine, there are 2 types of HLH: familial and acquired. Familial HLH accounts for about 25% of cases and families pass down the condition.
In a study conducted in Japan by Iishi et al., the male/female ratio was 0.94. Also, the incidence of FHL was estimated as 1 in 50,000 to 300,000 live births in Japan.
According to the NORD, in adults, men are slightly more affected than females.
DelveInsight's "Hemophagocytic Lymphohistiocytosis Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Hemophagocytic Lymphohistiocytosis market Size and Share, historical and forecasted epidemiology analysis as well as the Hemophagocytic Lymphohistiocytosis market trends in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
For more information on Hemophagocytic Lymphohistiocytosis market, visit: https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market
Keratoconus Market Analysis
In 2017, the total diagnosed prevalent population of Keratoconus in 7MM was 1,602,427. The diagnosed prevalent cases of Keratoconus in the United States was 550,047 while Germany and Japan had 218,772 and 240,591 diagnosed prevalent cases respectively in 2017.
The market size of Keratoconus in the seven major markets was USD 2,456 million in 2017.
Some of the key players in the Keratoconus market includes Avedro, Glaukos Corporation, Sooft Italia, Lightmed/OptiMed, Peschke Meditrade GmbH and iVeena Delivery Systems.
For more information on Keratoconus market, visit:
https://www.delveinsight.com/report-store/keratoconus-market
Cervical Cancer: Screening and Prevention
The total CervicalCancer prevalence in the 7MM (the US, EU5 (the UK, Germany, Spain, Italy, and France) and Japan) was found to be 43,514 in 2017. The UnitedStates topped the charts for maximum Cervical cancer prevalence with Spain accounting for the least number of cases in the 7MM.
Screening, coupled with HPV vaccination, has the potential to prevent Cervical cancer. Today, screening has become such a refined tool that has helped researchers to understand cancer almost completely.
The key players in the HPV Vaccine market include GSK and Merck.
For more details, visit:
https://www.delveinsight.com/blog/cervical-cancer-screening/
Peripheral Nerve Injuries Market
In 2017, the number of Peripheral Nerve Injuries cases in the 7MM was 3,889,176. The total number of Peripheral Nerve Injuries cases in the US was found to be 1,645,218 while Japan had around 848,800 cases.
The market size of Peripheral Nerve Injuries in the seven major markets was USD 2,182.82 million in 2017.
Some of the key players in the Peripheral Nerve Injuries market includes Toyobo, Polyganics, Axogen Corporation, Neuraptive Therapeutics, Silk Biomaterials, Orthocell Limited and others.
For more details visit:
https://www.delveinsight.com/report-store/peripheral-nerve-injuries-market
Alternative Medicine
Alternative Medicine is often referred to as “integrative,” or “complementary” medicine, including a wide range of medical treatments, products, practices, and healthcare systems that are not a part of standard/ conventional medical care.
Worldwide a significant number of people irrespective of their age, education, and status rely on various forms of Alternative Medicine to treat or ameliorate disease.
Alternative Medicine which follows a whole body care approach are generally less expensive and uses natural products such as oils, herbs, metals, and minerals.
Some of the most Alternative Medicine such as Homeopathy, Naturopathy, Ayurvedic Medicine, Unani Medicine, Siddha, chiropractic, aromatherapy, meditation, are gaining popularity in western countries, people are an option for these Alternative Medicine to treat disease and illness.
For more details on different types of Alternative Medicine, visit: https://www.delveinsight.com/blog/alternative-medicine/
Multiple Myeloma Market
DelveInsight estimated an overall Multiple myeloma incidence of 85,971 cases in the eight major markets (i.e the United States, EU5, Japan, and China). Among the 8MM, the United States accounted for the highest Multiple Myeloma incident cases, and as per the estimates, the incidence cases are expected to increase during the forecast period 2020-30 steadily. It has observed that men are more likely to get diagnosed with Multiple myeloma than women in 8MM.
In the 8MM, the Multiple myeloma therapeutics market size was found to be USD 14,111 million in 2017, which is expected to increase during the study period (2017–2030).
Some of the key companies involved in developing therapies for Multiple Myeloma includes GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca, and many others.
For more details on Multiple Myeloma Market, visit: https://www.delveinsight.com/blog/multiple-myeloma-market/
Healthcare Delivery System
The health system or healthcare delivery system consists of a broad spectrum of activities and people comprising patients, families, communities, populations, and organizations along with the policies, regulations, promotions, and laws that have a direct and indirect impact on patient care.
The delivery system or structure varies according to the needs and resources of the country. The healthcare delivery system across countries are mostly categorized into four parts namely Primary Care, Secondary Care, Tertiary Care, and Quaternary Care, to fulfill the health needs of its citizens.
The healthcare delivery system during the past decades has observed many revolutionary changes and is expected to do so in the coming years. Technology is one of the key elements, set to transform the health delivery system in the future. Telehealth and telemedicine services through remote patient care are expected to bring revolutionary changes in the Healthcare Delivery System in the upcoming years in the remote areas.
To read more on Healthcare Delivery System visit: https://www.delveinsight.com/blog/healthcare-delivery-system/
Hereditary Angioedema Market
In 2017 the total diagnosed prevalent population of Hereditary Angioedema in 7MM was 14,435. In France the prevalent cases of Hereditary Angioedema was found to be 1,346, while the UK and Spain had 1,301 and 537 prevalent cases in 2017.
In 2017, the Hereditary Angioedema Market Size was USD 1,741.75 million in seven major markets, which is expected to increase during the forecast period 2017-2030.
Some of the key players in the Hereditary Angioedema Market includes BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, and many others.
For more detailed information on Hereditary Angioedema Market, visit: https://www.delveinsight.com/report-store/hereditary-angioedema-market
Warm Autoimmune Hemolytic Anemia (WAIHA) Market
The total prevalent population of Warm Autoimmune Hemolytic Anemia in 7MM was 82,045 in 2017. Among the seven major markets it is observed that the females are more affected with WAIHA as compared to males.
In 2017 the market size of Warm Autoimmune Hemolytic Anemia (WAIHA) in 7MM was USD 368 million, which is expected to increase during the forecast period (2017-2030).
Some of the key players involved in developing therapies for WAIHA include Rigel Pharmaceuticals, Apellis Pharmaceuticals, Momenta Pharmaceuticals, Immunovant, Alexion Pharmaceuticals, Sanofi and many others.
For more details on Warm Autoimmune Hemolytic Anemia (WAIHA) market includes: https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
Keratoconus Market
At present, most of the pharma giants consider Keratoconus as a rare disease; there is often a debate on the understanding of the actual prevalence of the disease.
Since the 90s, the advancement in diagnostic tools such as corneal topography has soared the diagnosis rate at a commendable rate. The improvement, recognition, and research progress has made the disease well-known.
Keratoconus awareness has prompted significant development of new and improved interventions that augment the established legacy treatments.
Sooft Italia, Peschke Meditrade GmbH, and Lightmed-OptiMed and Avedro, Inc. are some of the key players involved in developing therapies for Keratoconus.
For more details, visit: https://www.delveinsight.com/blog/keratoconus-market/
Rosacea Treatment Market
Rosacea, a characteristic inflammatory condition affects the skin especially the face resulting in facial erythema or redness. Around one in 10 people in the world is affected by rosacea. The condition can be controlled differently; however, there is no standard cure for the disease. The treatment also varies with the subtype of rosacea. The treatment is prescribed according to the dominant features of the disease.
To meet the unmet needs some of the key pharma players such as Foamix Pharmaceuticals, Sol-Gel Technologies, Accuitis, Hovione, Afecta Pharmaceuticals, and AOBiome Therapeutics are involved in developing novel therapies for the rosacea.
For more detailed information, visit:
https://www.delveinsight.com/blog/rosacea-treatment-market/
Dravet Syndrome Market
As per DelveInsight’s estimates, the total Dravet Syndrome incidence in the 7MM (the US, EU5 (the UK, Italy, Germany, Spain, France) and Japan) was 30,820.
The Dravet syndrome market size was estimated to be USD 79.1 Million in 2017, which is expected to increase at a significant CAGR during the study period (2017–2030) owing to pipeline #therapies to be launched in coming years. Among all the geographies studied, the United States accounted for the largest Dravet Syndrome market size.
Some of the key players in the Dravet syndrome market include Ovid Therapeutics, Takeda, Epygenix Therapeutics, Inc., PTC Therapeutics, Inc. and many others.
For more details visit:
https://www.delveinsight.com/blog/dravet-syndrome-market/
Exocrine Pancreatic Insufficiency Market
As per DelveInsight’s EPI Epidemiological analysis, a total of 80,641 Exocrine Pancreatic Insufficiency cases were reported due to Acute Pancreatitis, and 237,255 cases due to Chronic Pancreatitis. At the same time, Cystic Fibrosis and Unresectable Pancreatic Cancer caused 62,204 and 59,036 EPI cases, respectively, in 2017 in the 7MM.
The market size of Exocrine Pancreatic Insufficiency in the seven major markets was estimated to be approximately USD 1,695.26 Million in 2017.
To address the unmet needs in the Exocrine Pancreatic Insufficiency market, pharma companies such as CHIESI FARMACEUTICI S.P.A., AzurRx BioPharma, Inc., and many others are investing in developing novel therapeutic approaches in their Exocrine Pancreatic Insufficiency pipeline to change the treatment landscape of EPI entirely.
For more details visit:
https://www.delveinsight.com/blog/exocrine-pancreatic-insufficiency-market/
Social Determinants Of Health (SDOH)
Social factors are also called social determinants of health (SDOH). The SDOH is the socioeconomic conditions prevailing in society that have an influence on the health of the people. Social determinants of health consist of a wide range of factors such as education, employment, economic policies, physical environment, public safety, healthy transport systems, social status and support policies, and many others. As per the WHO, SDOH are the conditions in which people are born, grow, work, live, and age, and the wider set of forces and systems shaping the conditions of daily life.
SDOH is an essential health element as it relies on bringing “Health equity” (or equity in health)‘. It reduce health disparities as it avoids any unfair, or remediable differences among groups of people based on their social, economical, and geographical differences.
For more detailed information on social determinants of health (SDOH), visit:
https://www.delveinsight.com/blog/social-determinants-of-health/
Dietary Modifications For Gastroparesis
Gastroparesis, often referred to as delayed gastric emptying, is a disorder affecting the movement of food from the stomach to the small intestine.
As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), “Gastroparesis is not common. Out of 100,000 people, about 10 men and 40 women have gastroparesis”. Various studies have demonstrated a gender bias for Gastroparesis; women are found to be more affected as compared to men.
As of now, there is no cure for gastroparesis, and it remains a long term irreversible condition. Dietary modification is first-line therapy for gastroparesis; it helps in maintaining nutrition, fluid content, electrolyte in the body and improving symptoms. Some of the effective dietary practices which are helpful in managing gastroparesis includes small meals with increased frequency, chewing food thoroughly, avoiding excess fibrous food items, consuming well cooked fruits and vegetables, taking multivitamins, reducing excess fat intake and many others.
For more details visit:
https://www.delveinsight.com/blog/dietary-approaches-for-gastroparesis/
Diffuse Large B-cell Lymphoma (DLBCL) Market
The total incident cases of Diffuse Large B-cell Lymphoma in 7MM was 67,743 in 2017. The incident population of DLBCL in the United States was 28,659, while Germany and Japan had 7,443 and 9,485 incident populations respectively in 2017.
The market Size of DLBCL in the seven major markets was USD 2,692 million in 2017.
The key players in the Diffuse Large B-cell Lymphoma market includes Bristol-Myers Squibb, Seattle Genetics, Takeda, ADC Therapeutics, Morphosys, Incyte, SymBio Pharmaceuticals, Denovo Biopharma, TG Therapeutics, Amgen, Bayer, Janssen, Pharmacyclics, Regeneron Pharmaceuticals, Celgene, Bristol Myers Squibb, Incyte Corporation, TCR2 Therapeutics, IMV, inc. & Merck, AstraZeneca, Autolus Therapeutics, Hoffmann-La Roche, Cellectar Bioscience, Debiopharm International and others.
For more detailed information on Diffuse Large B-cell Lymphoma market, visit:
https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
Sarcopenia Market
The total prevalent population of Sarcopenia in 7MM was 33,321,576 in 2017. The total prevalent cases of Sarcopenia in the United States was found to be 749,154 in 2017. The prevalence of Sarcopenia by gender in the US in 2017 was 9,932,700 Males and 7,867,838 Females.
In 2017, the therapeutic market of Sarcopenia in 7MM was USD 1166.26 Million.
Some of the key companies in the Sarcopenia market include Biophytis, Novartis, Amazentis, Eli Lilly and Company, Regeneron Pharmaceuticals, Sanofi, Immunoforge and many others.
For more information on Sarcopenia market visit:
https://www.delveinsight.com/report-store/sarcopenia-market
Cutaneous Lupus Erythematosus
The total prevalent population of Cutaneous Lupus Erythematosus in the 7MM was 327,569 in 2017. The Cutaneous Lupus Erythematosus cases in the United States in 2017 was 182,765.
The Market Size of Cutaneous Lupus Erythematosus in 7MM was found to be USD 485.27 Million in 2017, according to DelveInsight, Cutaneous Lupus Erythematosus Market in the 7MM is expected to change during the study period.
Some of the key players in the Cutaneous Lupus Erythematosus market include Biogen, Pfizer, Galapagos NV, Gilead Sciences, LEO Pharma/ Japan Tobacco, VIELABIO and many others.
For more detailed information on Cutaneous Lupus Erythematosus market, visit:
https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
Joined Feb 2020
